RSV

Moderna on Tuesday reported positive results for its experimental respiratory syncytial virus vaccine, saying the shot was about 84% effective in preventing ...

The results were announced in October 2022, several months after Pfizer had revealed preliminary [data](https://www.biopharmadive.com/news/pfizer-follows-gsk-with-positive-phase-3-results-for-rsv-vaccine/630536/) for its RSV vaccine. Safety will continue to be monitored as the study progresses. Along with GSK, Pfizer and Moderna, Johnson & Johnson, Sanofi and Bavarian Nordic are also testing RSV vaccines. According to the - Moderna’s Phase 3 trial measured how well the vaccine prevented at least two symptoms of RSV-associated respiratory infection in adults older than 60. The infection can be particularly dangerous in children younger than 5 and in adults over the age of 65.

Moderna and Pfizer produced Covid vaccines in record time, and now novel RSV vaccines are on a similar trajectory for both drug companies' R&D platforms.

"What the CDC said was it saw a small signal in a database and discovered nothing," and he added that Pfizer also did its own investigation in Israel, the U.S. "If you look at data, the clinical data run by independent data safety monitoring boards [the FDA in the U.S. The RSV approval process is just one part of a widening vaccine industry for these two companies. We can use the same people, the same equipment and raw materials as the Covid vaccine." "This is a transition year," Bourla said, as Covid shots move from a government funded business to a commercial business. ... As we looked at the impact on the world and hospitalizations and deaths, we said we need to find a solution." The RSV successes come after a particularly bad RSV season in the U.S. Pfizer, he said, already has priority review in the FDA approval process because of the data set's strength and because the disease does not have vaccine. and the world, it was No. Bancel told CNBC that common side effects of this type of virus vaccine, such as fever, were only slightly higher in those receiving the RSV shot in the trial (4%) versus those in the control group getting a placebo (2.8%). That caught the attention of Moderna, which for years has been working on its mRNA technology. 2 cause of hospitalizations in the U.S.

The respiratory syncytial virus, which dominated respiratory infections just a few months ago, does not only cause breathing problems in babies and toddlers but ...

for more features. And in a large clinical trial, those 60 and older who received the RSV vaccine were almost 84-percent less likely to develop symptoms compared to those who didn't receive the shot.

Moderna announced positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus.

This candidate employs the same lipid nanoparticle envelope as the company’s COVID-19 vaccine, Spikevax. [priority review](https://www.biospace.com/article/gsk-rsv-vaccine-candidate-snags-priority-review-designation/) to GlaxoSmithKline’s RSV vaccine candidate for older adults. [announced](https://www.biospace.com/article/releases/moderna-announces-mrna-1345-an-investigational-respiratory-syncytial-virus-rsv-vaccine-has-met-primary-efficacy-endpoints-in-phase-3-trial-in-older-adults/) positive topline results from a Phase III trial with older adults and a vaccine candidate aimed at preventing respiratory syncytial virus (RSV) called mRNA-1345.

A new passive RSV immunization that developers say is under federal review got started with twin baby girls at Upstate Medical University.

But she said they did get a spot in medical history when AstraZeneca asked to use their photos for research papers. Back in the 1960s, a "It has to be given monthly," Domachowske said. And you can see the pharma people that were attending, taking notes, calling their colleagues saying, 'Stop, stop the work.” That’s where we’d been stuck for years until 2014, when Domachowsk attended a medical conference in Argentina. [recent RSV surge](https://www.waer.org/2022-11-17/golisano-runs-low-on-cribs-cancels-elective-procedures-amid-rsv-surge) overwhelmed hospitals across the country. But Meany was worried about it back then after seeing multiple friends with kids in the hospital for the illness — [up to 80,000 children](https://www.cdc.gov/rsv/research/index.html) under five are admitted for RSV each year. But for years, he’s worked with AstraZeneca on a monoclonal antibody that's a ready-made immune defense against RSV. The second pregnancy for Cheryl Meany quickly turned from joyful to terrifying. Domachowske expects a greenlight by spring and nirsevimab to be on available by the next RSV season in the fall. “Everyone is sitting there staring with their mouths gaping open like, 'This is why all of our work hasn't led to anything for decades," Domachowske said. So she needed a moment to process when her husband proposed enrolling the soon-to-be-born babies in an experimental study for an RSV immunization.

mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults ...

The interim analysis was based on 64 cases of RSV-LRTD with two or more symptoms, of which 55 occurred in the placebo group and 9 occurred in the mRNA-1345 group, and 20 cases of RSV-LRTD with three or more symptoms, of which 17 cases were observed in the placebo group compared with three cases observed in the mRNA-1345 group. The overall rate of Grade 3 or greater solicited local adverse reactions was 3.2% for mRNA-1345 and 1.7% for placebo. The overall rate of severe (Grade 3 or greater) solicited systemic adverse reactions was 4.0% for mRNA-1345 and 2.8% for placebo. "This trial will help to understand the role of severe acute respiratory infections in older adult populations and inform the future implementation of vaccines in adults in lower-resource areas." Following review by an independent Data and Safety Monitoring Board (DSMB), the primary efficacy endpoints have been met, including vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-associated lower respiratory tract disease (RSV-LRTD) as defined by two or more symptoms. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults.

An experimental RSV vaccine demonstrated an 83.7% efficiency against the virus in older adults, biotech company Moderna announced Wednesday.